UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8	8-K
---------------	-----

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 16, 2022

INHIBIKASE THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

	Delaware (State or Other Jurisdiction of Incorporation)	001-39676 (Commission File Number)	26-3407249 (IRS Employer Identification No.)
3350 Riverwood Parkway SE, Suite 1900 Atlanta, Georgia (Address of Principal Executive Offices)			30339 (Zip Code)
	Registrant's Teleph	none Number, Including Area Code: (67	78) 392-3419
	(Former Name	N/A e or Former Address, if Changed Since Last Re	eport)
	appropriate box below if the Form 8-K filing is int provisions (see General Instruction A.2. below):	tended to simultaneously satisfy the filing	obligation of the registrant under any of the
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)		
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		
Securities	registered pursuant to Section 12(b) of the Act:		
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered
C	Common Stock, \$0.001 par value	IKT	The Nasdaq Stock Market LLC
	check mark whether the registrant is an emerging Rule 12b-2 of the Securities Exchange Act of 193		of the Securities Act of 1933 (§230.405 of this
Emerging	growth company ⊠		
	ging growth company, indicate by check mark if the financial accounting standards provided pursuant to		ended transition period for complying with any new

Item 7.01 Regulation FD Disclosure.

On September 16, 2022, Inhibikase Therapeutics, Inc. (the "Company") made a conference presentation at the International Congress of Parkinson's Disease and Movement Disorders® in Madrid, Spain. A copy of the Company's presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K speaks only as of the date hereof. While the Company may elect to update the information in this Current Report on Form 8-K in the future, the Company disclaims any obligation to do so except to the extent required by applicable law.

The information furnished in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K is not incorporated by reference into any filings of the Company made under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in the filing unless specifically stated so therein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 Number
 Description

 99.1
 Conference Presentation of Inhibikase Therapeutics, Inc.

 104
 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 16, 2022 INHIBIKASE THERAPEUTICS, INC.

By: /S/ MILTON H. WERNER

Milton H. Werner, Ph.D. President and Chief Executive Officer




IkT-148009 As A Potential Disease-Modifying Therapy in Parkinson's Disease


Poster 789

Werner MH, ^{1,7} Karuppagounder SS, ^{2,3} Rush R, ¹ Kelly T, ¹ Dawson TM, ^{2,3,5,7} Dawson VL^{2,4,6,7}

'Inhibitase Therapeutics, Inc., Atlanta, GA, 30339, USA; 'Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; 'Department of Physiology, Johns Hopkins University School of Medic







Conclusion: c-Abl is essential for disease initiation and progression Prochat Acad Sol U.S.A.187-166919 (2016) J. Clin Insect. 162.2076 (2016)





